Commentary on “Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911).” Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France.: Lancet 2012;380(9858):2018–27. doi: 10.1016/S0140-6736(12)61253-7. [Epub 2012 Oct 19]

Autor: Ritter, Mark A.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations April 2014 32(3):372-373

Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911): Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset J-F, Piérart M, European Organisation for Research and Treatment of Cancer (EORTC) Radiotherapy and Genito-urinary Groups, European Organisation for Research and Treatment of Cancer (EORTC) Data Center–Biostatistics, Brussels, Belgium

Autor: Ritter, Mark A.

Publikováno v: In Urologic Oncology: Seminars and Original Investigations 2006 24(4):374-374

Commentary on 'Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: Long-term results of a randomised controlled trial (EORTC trial 22911).' Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Department of Radiation Oncology, Centre Hospitalier Universitaire A Michallon, Grenoble, France

Autor: Mark A. Ritter

Publikováno v: Urologic Oncology: Seminars and Original Investigations. 32:372-373

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16dfa2438160a2670983c83298a69a49
https://doi.org/10.1016/j.urolonc.2013.09.023

Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.

Autor: Bührer E; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., D'Haese D; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Daugaard G; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., de Wit R; Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Albany C; Horizon Oncology Research, 1345 Unity PI Ste 345, Lafayette, IN, United States of America., Tryakin A; N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation., Fizazi K; Institut Gustave Roussy, University of Paris Saclay, Villejuif, France., Stahl O; Department of Oncology, Skåne University Hospital, Lund, Sweden., Gietema JA; University Medical Centre Groningen, Groningen, the Netherlands., De Giorgi U; IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy and the Italian Germ Cell Cancer Group (IGG), Italy., Cafferty FH; Medical Research Council Clinical Trials Unit, University College London (UCL), London, United Kingdom; Institute of Cancer Research Clinical Trials and Statistics Unit, Sutton, United Kingdom., Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Tandstad T; The Cancer Clinic, St Olavs University Hospital and Department of Clinical and Molecular Medicine, The Norwegian University of Science and Technology, Trondheim, Norway., Huddart RA; Institute of Cancer Research, Sutton, United Kingdom., Necchi A; Vita-Salute San Raffaele University, Milan, Italy; Department of Medical Oncology, IRCCS San Raffaele Hospital, Milan, Italy., Sweeney CJ; South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia., Garcia-Del-Muro X; Catalan Institute of Oncology, IDIBELL Institute of Research, University of Barcelona, Barcelona, Spain., Heng DYC; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Lorch A; Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland; Department of Urology, University Hospital Dusseldorf, Dusseldorf, Germany., Chovanec M; 2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, Bratislava, Slovakia; Cancer Research Institute, Biomedical Center, Slovak Academy of Sciences, Bratislava, Slovakia., Winquist E; Division of Medical Oncology, Western University and London Health Sciences Centre, London, Ontario, Canada., Grimison P; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, Australia., Feldman DR; Memorial Sloan Kettering Cancer Centre, New York, NY, United States of America; Weill Medical College of Cornell University, New York, NY, United States of America., Terbuch A; Division of Oncology, Department of Internal Medicine, Medical University of Graz, Graz, Austria., Hentrich M; Department of Hematology and Oncology, Red Cross Hospital, University of Munich, Munich, Germany., Bokemeyer C; Department of Oncology, Hematology and BMT with Section Pneumology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany., Negaard H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Fankhauser C; University of Zurich, Zurich, Switzerland., Shamash J; St Bartholomew's Hospital, London, United Kingdom., Vaughn DJ; University of Pennsylvania, Philadelphia, PA, United States of America., Sternberg CN; Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy., Heidenreich A; Department of Urology, Uro-Oncology, Robot-Assisted and Specialized Urologic Surgery, University Hospital Cologne, Cologne, Germany; Department of Urology, Medical University Vienna, Austria., Collette L; European Organisation for Research and Treatment of Cancer, Brussels, Belgium., Gillessen S; Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland; Universita della Svizzera Italiana (USI), Lugano, Switzerland., Beyer J; University Department of Medical Oncology, Inselspital, University Hospital, University of Bern, Bern, Switzerland. Electronic address: joerg.beyer@insel.ch.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 114042. Date of Electronic Publication: 2024 Mar 30.

Synthesis, characterization and structure solution of ULS-1 |ETMA8(H2O)20|[Si24O48(OH)8], a layered silicate composed of half-sodalite cages

Autor: Miller, Mark A., Miller, Stuart R., Broach, Robert W., Galey, Melissa M., Prabhakar, Sesh, Lyons, Brendon, Nicholas, Collette L., Nicholas, Christopher P.

Publikováno v: In Microporous and Mesoporous Materials 15 January 2015 202:250-258